Skip to content
6 physician-led programs. Care and medication, both priced before you start.See all programs
GLP-1 receptor agonist

Wegovy

semaglutide

FDA-approved for chronic weight management. Once-weekly subcutaneous injection.

Mechanism

How it works

Semaglutide mimics a naturally occurring gut hormone (GLP-1) that the body releases after meals. It slows gastric emptying, reduces appetite-driven food cues, and supports the body's own satiety signaling.

Technical detail
Semaglutide is a long-acting GLP-1 receptor agonist with a half-life of approximately 7 days, structurally modified for albumin binding. It produces glucose-dependent insulin secretion, suppresses inappropriate glucagon, slows gastric emptying, and acts centrally on hypothalamic appetite circuits.
At Vayra

How we use it

Wegovy is part of our GLP-1 Weight Optimization program for patients meeting FDA on-label criteria, BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity. Continuity is a priority, you will see the same physician whenever clinically possible; 45-min initial visit, 30-min monthly check-ins, unlimited secure messaging in between.

Route & titration

What to expect

Once-weekly subcutaneous self-administered injection. Dose escalation follows the FDA-approved schedule: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, advancing approximately monthly per tolerance. Maintenance dose is 2.4 mg weekly.

Safety

Adverse effects and contraindications

Common
  • Nausea, often dose-related and most pronounced during titration
  • Diarrhea
  • Constipation
  • Reduced appetite
  • Fatigue in the first weeks
Infrequent
  • Headache
  • Injection-site irritation
  • Dizziness
Serious
  • Pancreatitis, discontinue if suspected
  • Gallbladder events (cholelithiasis, cholecystitis)
  • Severe GI events requiring hospitalization
  • Thyroid C-cell tumors, boxed warning per the FDA label
Contraindications
  • Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
  • Pregnancy or planned pregnancy in the next 2 months
  • Severe gastroparesis
Evidence

What the literature says

Published trials of semaglutide for chronic weight management (the STEP program) report substantial mean weight reduction at one year. Effects depend on continued use; published data indicate partial weight regain after discontinuation. Vayra does not claim specific outcomes for any patient.

Dispensing

How it reaches you

Branded Wegovy is prescribed and dispensed through a separately licensed retail/specialty pharmacy partner. Your Vayra membership covers your physician relationship, lab review, and the full clinical practice; your medication is priced separately and shown with your total.

HIPAA compliant
Licensed physicians in 40+ states
Licensed Pharmacy · Partner
No insurance billing · FSA / HSA eligible

Begin a documented physician visit.

Prescribing is the outcome of a clinical encounter, not a checkout flow. Your assessment takes about eight minutes; nothing is billed until you and your physician agree on a protocol.

Begin assessment

Eight minutes to start. A lifetime of difference.

A Vayra-affiliated physician reviews your case within 24 hours. No insurance billed. Cancel anytime, two taps.